Pharming Group N.V. (PHAR) Stock

About Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Pharming Group N.V. is headquartered in NL.

Pharming Group N.V. (PHAR) stock trades at $9.68 with a market capitalization of $685.13M. The stock is valued at a price-to-earnings (P/E) ratio of 66.30, price-to-book of 2.68, price-to-sales of 1.88. Over the past 52 weeks the stock has ranged between $9.62 and $21.34, and currently trades 54.6% below its 52-week high.

On profitability, Pharming Group N.V. generates a return on equity (ROE) of 3.52%, return on capital employed of 3.91%, an operating margin of 4.00%, a net profit margin of 2.57%.

Official website: www.pharming.com